Stock of California Firm Jumps 17 Percent on News of Golden State Award
Google chart
ImmunoCellular Therapeutics’ stock price shot up 17 percent today in the wake of formal approval of a $20 million award from the California stem cell agency for a clinical trial involving a rare brain cancer.
The price has been climbing since last week when the California Stem Cell Report first disclosed that the company was set to secure the…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.